Citation Tools
PDFClinical/translational cancer immunotherapy
Original research
Phase II study of durvalumab (anti-PD-L1) and trametinib (MEKi) in microsatellite stable (MSS) metastatic colorectal cancer (mCRC)
Download to a citation manager
Download the citation for this article by clicking on one of the following citation managers:
- Cite this article as:
- Phase II study of durvalumab (anti-PD-L1) and trametinib (MEKi) in microsatellite stable (MSS) metastatic colorectal cancer (mCRC)